See What HealthDay Can Do For You
Contact Us

Antibody Detects, Predicts Rheumatoid Arthritis Outcome

Test for CCP antibodies allows early detection, even in seronegative patients

FRIDAY, April 21 (HealthDay News) -- A second generation anti-cyclic citrullinated peptide (anti-CCP2) antibody test is useful for early detection of rheumatoid arthritis and may predict radiographic and functional outcomes, according to a report in the April issue of Rheumatology.

Mark A. Quinn and colleagues from Chapel Allerton Hospital in Leeds, U.K., used questionnaires and X-rays to assess the function of 182 rheumatoid arthritis patients and 121 connective tissue disease controls at 0, 12 and 24 months after anti-CCP2 antibody levels were measured.

The investigators found the test demonstrated a specificity of 91 percent and a sensitivity of 81 percent compared with controls. The CCP2 also predicted disease and poor functional response in rheumatoid factor-negative subgroups where the specificity was 92 percent and the sensitivity was 60 percent.

Early detection of rheumatoid arthritis is crucial to treatment of the disease since early intervention has a disproportionate effect on outcome, the authors indicate. "This study confirms the diagnostic utility of anti-CCP2 antibodies in early rheumatoid arthritis, particularly in seronegative patients, in whom anti-CCP2 positivity also conferred prognostic utility for radiographic and functional outcomes," they conclude.

Abstract
Full Text (subscription or payment may be required)

Physician's Briefing

HealthDay

HealthDay is the world’s largest syndicator of health news and content, and providers of custom health/medical content.

Consumer Health News

A health news feed, reviewing the latest and most topical health stories.

Professional News

A news feed for Health Care Professionals (HCPs), reviewing latest medical research and approvals.